US Bancorp
CBIO

US Bancorp’s Crescent Biopharma CBIO Stock Holding History

US Bancorp’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.25K Buy
+403
New +$7.87K ﹤0.01% 3553

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

US Bancorp's CBIO Position: Q2 2026 in Review

US Bancorp opened a new position in Crescent Biopharma (CBIO) in Q2 2026: 403 shares worth $7.25K. The stake represents ﹤0.01% of the portfolio and ranks #3553 among its holdings.

82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • US Bancorp held 403 shares of Crescent Biopharma worth $7.25K as of Q2 2026.
  • Crescent Biopharma was a new US Bancorp position in Q2 2026.
  • Crescent Biopharma made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3553 holding.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.